Expect continued downward pressure as the small offering highlights severe cash constraints. Monitor for further dilutive financing within 12 months, particularly if the warrant reset triggers (stock below $9). The $2M NIH grant is non-dilutive but insufficient to alter the trajectory. Watch for any NCT commercialization milestones or partnership announcements as potential catalysts.
Price Chart
Executive Summary
Exozymes is raising $565,206 net proceeds via a registered direct offering of 71,110 shares and 35,555 warrants, priced at $8.99 per share (units of 2 shares + 1 warrant at $18.00). The company has a going-concern warning with only $1.44M cash as of March 31, 2026, and an accumulated deficit of $23.47M. The tiny offering size underscores persistent cash burn and imminent need for additional capital, while warrants include a reset provision to $0.001 if the company sells stock below $9.00 within a year, threatening severe future dilution.
Key Facts
- Offering: 35,555 units at $18.00/unit, each unit = 2 shares + 1 warrant, total 71,110 shares and 35,555 warrants.
- Net proceeds to company: ~$565,206 after placement agent fees and expenses.
- Warrant exercise price: $11.24, exercisable from June 5, 2027 to June 5, 2031, with reset to $0.001 if company sells stock below offering price before June 5, 2027.
- Going concern warning: cash $1.44M, accumulated deficit $23.47M as of March 31, 2026; company expects further losses.
- Placement agent MDB Capital is an affiliate (MDB Holdings owns 43.9%), creating a conflict of interest.
- Stock closed at $8.42 on June 29, 2026; offering price per share $8.99 (slight premium).
- Pre-revenue biotech focused on cell-free enzyme platform for nutraceuticals/pharmaceuticals; lead candidate NCT (N-trans-caffeoyltyramine).
Financial Impact
Immediate dilution of ~0.8% from 71,110 new shares; potential additional dilution from 35,555 warrants with reset feature. Net cash infusion of $565k is minimal relative to $1.44M cash balance and likely burn rate.
Risk Factors
- Going concern risk: insufficient capital to fund operations beyond near term.
- Warrant reset to $0.001 could cause massive dilution if stock trades below $9 within a year.
- High reliance on MDB Capital (placement agent with 43.9% ownership and board representation) raises governance concerns.
- Pre-revenue company with no approved products; NCT program still in early commercial stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-031284 |
| Document: 0001493152-26-031284-index-headers.html | 0001493152-26-031284 |
| Document: 0001493152-26-031284-index.html | 0001493152-26-031284 |
| Document: 0001493152-26-031284.txt | 0001493152-26-031284 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $5.25 | awaiting T+20 | — | $3.62 (−31.05%) |
Sep 28, 2026 28d ago | DEFA14A | $6.10 | awaiting T+20 | — | $3.62 (−40.66%) |
Sep 28, 2026 28d ago | DEF 14A | $6.10 | awaiting T+20 | — | $3.62 (−40.66%) |
Sep 18, 2026 5w ago | 8-K | $6.44 $4.09 | ▼ −36.44% | ▼ −36.65% | $3.62 (−43.75%) |
Jun 30, 2026 16w ago | 424B5 | $8.50 $4.40 | ▲ +48.24% | ▲ +46.05% | $3.62 (+57.41%) |
Jun 25, 2026 17w ago | 8-K | $8.03 $4.70 | ▼ −41.47% | ▼ −42.73% | $3.62 (−54.92%) |
Jun 17, 2026 18w ago | 8-K | $7.83 $6.22 | ▲ +20.56% | ▲ +21.09% | $3.62 (+53.77%) |
Jun 8, 2026 20w ago | 8-K | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.62 (+58.00%) |
Jun 8, 2026 20w ago | 424B5 | $8.62 $8.14 | ▲ +5.57% | ▲ +7.20% | $3.62 (+58.00%) |
Jun 4, 2026 20w ago | 424B5 | $9.35 $8.48 | ▲ +9.30% | ▲ +7.93% | $3.62 (+61.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers